Trial site
MedStar Good Samaritan Hospital
Baltimore, Maryland 21239, United StatesNot linked to an institution yet
- 17running trials
- 5closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 2/35 trials
- Phase 22 trials
- Status
- Active, not recruiting12 trials
- Completed5 trials
- Recruiting4 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Alliance for Clinical Trials in Oncology5 trials
- NRG Oncology5 trials
- Eli Lilly and Company4 trials
- National Cancer Institute (NCI)3 trials
- Integra LifeSciences Corporation1 trial
- and 4 more
Running trials
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: Adline Ghazi (principal investigator)
Active, not recruiting
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source
Enrolling by invitation
A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
NCT06453187· Integra LifeSciences Corporation· Source
Active, not recruiting
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133· Phase 3· vTv Therapeutics· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Kristen D. Whitaker (principal investigator)
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107· Phase 2· Zucara Therapeutics Inc.· Source
Contact: Lumanti Manandhar
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Benjamin A. Weinberg (principal investigator)
Active, not recruiting
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
NCT04137107· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error